Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant

Drug addiction: Dual-use vaccine shows promise for heroin and HIV A vaccine designed to treat heroin addiction while at the same time preventing HIV infection elicited strong immune responses in mice. Scientists from the US government led by Carl Alving from the Walter Reed Army Institute of Researc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Oscar B. Torres, Gary R. Matyas, Mangala Rao, Kristina K. Peachman, Rashmi Jalah, Zoltan Beck, Nelson L. Michael, Kenner C. Rice, Arthur E. Jacobson, Carl R. Alving
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/85620eb333114e65ac36983c03f03f2e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:85620eb333114e65ac36983c03f03f2e
record_format	dspace
spelling	oai:doaj.org-article:85620eb333114e65ac36983c03f03f2e2021-12-02T12:30:33ZHeroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant10.1038/s41541-017-0013-92059-0105https://doaj.org/article/85620eb333114e65ac36983c03f03f2e2017-05-01T00:00:00Zhttps://doi.org/10.1038/s41541-017-0013-9https://doaj.org/toc/2059-0105Drug addiction: Dual-use vaccine shows promise for heroin and HIV A vaccine designed to treat heroin addiction while at the same time preventing HIV infection elicited strong immune responses in mice. Scientists from the US government led by Carl Alving from the Walter Reed Army Institute of Research in Bethesda, Maryland, created a dual vaccine formulated with three main components: a segment of a protein expressed on the surface of HIV; synthetic molecules that resemble heroin and its degradation products; and a potent adjuvant to stimulate the immune system. Mice immunized with this vaccine had high antibody titers against the HIV surface protein as well as heroin and its derivatives. These mice also showed dulled responses to injected heroin. The findings suggest this vaccine strategy could help fight heroin abuse and the high risk of HIV infection among intravenous drug users.Oscar B. TorresGary R. MatyasMangala RaoKristina K. PeachmanRashmi JalahZoltan BeckNelson L. MichaelKenner C. RiceArthur E. JacobsonCarl R. AlvingNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 2, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Oscar B. Torres Gary R. Matyas Mangala Rao Kristina K. Peachman Rashmi Jalah Zoltan Beck Nelson L. Michael Kenner C. Rice Arthur E. Jacobson Carl R. Alving Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant
description	Drug addiction: Dual-use vaccine shows promise for heroin and HIV A vaccine designed to treat heroin addiction while at the same time preventing HIV infection elicited strong immune responses in mice. Scientists from the US government led by Carl Alving from the Walter Reed Army Institute of Research in Bethesda, Maryland, created a dual vaccine formulated with three main components: a segment of a protein expressed on the surface of HIV; synthetic molecules that resemble heroin and its degradation products; and a potent adjuvant to stimulate the immune system. Mice immunized with this vaccine had high antibody titers against the HIV surface protein as well as heroin and its derivatives. These mice also showed dulled responses to injected heroin. The findings suggest this vaccine strategy could help fight heroin abuse and the high risk of HIV infection among intravenous drug users.
format	article
author	Oscar B. Torres Gary R. Matyas Mangala Rao Kristina K. Peachman Rashmi Jalah Zoltan Beck Nelson L. Michael Kenner C. Rice Arthur E. Jacobson Carl R. Alving
author_facet	Oscar B. Torres Gary R. Matyas Mangala Rao Kristina K. Peachman Rashmi Jalah Zoltan Beck Nelson L. Michael Kenner C. Rice Arthur E. Jacobson Carl R. Alving
author_sort	Oscar B. Torres
title	Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant
title_short	Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant
title_full	Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant
title_fullStr	Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant
title_full_unstemmed	Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant
title_sort	heroin-hiv-1 (h2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an hiv-1 envelope v2 peptide with liposomal lipid a as an adjuvant
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/85620eb333114e65ac36983c03f03f2e
work_keys_str_mv	AT oscarbtorres heroinhiv1h2vaccineinductionofdualimmunologiceffectswithaheroinhaptenconjugateandanhiv1envelopev2peptidewithliposomallipidaasanadjuvant AT garyrmatyas heroinhiv1h2vaccineinductionofdualimmunologiceffectswithaheroinhaptenconjugateandanhiv1envelopev2peptidewithliposomallipidaasanadjuvant AT mangalarao heroinhiv1h2vaccineinductionofdualimmunologiceffectswithaheroinhaptenconjugateandanhiv1envelopev2peptidewithliposomallipidaasanadjuvant AT kristinakpeachman heroinhiv1h2vaccineinductionofdualimmunologiceffectswithaheroinhaptenconjugateandanhiv1envelopev2peptidewithliposomallipidaasanadjuvant AT rashmijalah heroinhiv1h2vaccineinductionofdualimmunologiceffectswithaheroinhaptenconjugateandanhiv1envelopev2peptidewithliposomallipidaasanadjuvant AT zoltanbeck heroinhiv1h2vaccineinductionofdualimmunologiceffectswithaheroinhaptenconjugateandanhiv1envelopev2peptidewithliposomallipidaasanadjuvant AT nelsonlmichael heroinhiv1h2vaccineinductionofdualimmunologiceffectswithaheroinhaptenconjugateandanhiv1envelopev2peptidewithliposomallipidaasanadjuvant AT kennercrice heroinhiv1h2vaccineinductionofdualimmunologiceffectswithaheroinhaptenconjugateandanhiv1envelopev2peptidewithliposomallipidaasanadjuvant AT arthurejacobson heroinhiv1h2vaccineinductionofdualimmunologiceffectswithaheroinhaptenconjugateandanhiv1envelopev2peptidewithliposomallipidaasanadjuvant AT carlralving heroinhiv1h2vaccineinductionofdualimmunologiceffectswithaheroinhaptenconjugateandanhiv1envelopev2peptidewithliposomallipidaasanadjuvant
_version_	1718394346271670272

Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant

Ejemplares similares